AstraZeneca

AstraZeneca's IMFINZI® (durvalumab) approved in the US for treating limited-stage small cell lung cancer (LS-SCLC) post-chemoradiotherapy, based on ADRIATIC Phase III trial showing a 27% reduction in death risk versus placebo. IMFINZI is the first systemic treatment to improve survival in LS-SCLC in four decades, with 57% of patients alive at three years.

AstraZeneca's IMFINZI® (durvalumab) approved by FDA for treating limited-stage small cell lung cancer (LS-SCLC) post-chemoradiotherapy. ADRIATIC Phase III trial showed 57% survival at three years, marking a significant advancement. IMFINZI reduces death risk by 27% and disease progression by 24% versus placebo, with manageable safety profile.

AstraZeneca's IMFINZI® (durvalumab) approved by FDA for limited-stage small cell lung cancer (LS-SCLC) treatment post-chemoradiotherapy, based on ADRIATIC Phase III trial showing 27% reduced death risk versus placebo. IMFINZI is the first systemic treatment improving survival for LS-SCLC in decades, with 57% of patients alive at three years.

AstraZeneca's Imfinzi (durvalumab) approved in the US for limited-stage small cell lung cancer (LS-SCLC) treatment, showing a 27% reduction in death risk versus placebo. ADRIATIC Phase III trial results demonstrated significant survival benefits, marking a breakthrough in LS-SCLC therapy.

AstraZeneca's IMFINZI® (durvalumab) approved by the FDA for treating limited-stage small cell lung cancer (LS-SCLC) after platinum-based chemotherapy and radiation therapy. The approval is based on the ADRIATIC Phase III trial results, showing improved survival rates and reduced risk of death and disease progression. IMFINZI is the first systemic treatment to demonstrate improved survival for LS-SCLC patients post-curative-intent chemoradiotherapy, with 57% of patients alive at three years. The drug also received approval in Switzerland and is under review in the EU, Japan, and other countries.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca is a leader in oncology, focusing on early detection and innovative treatments for lung cancer and immuno-oncology, aiming to redefine cancer care and eliminate it as a cause of death.

The precision medicine market is projected to grow by USD 66.2 billion from 2024-2028, driven by the rising prevalence of chronic diseases and the increasing use of AI and ML. However, data privacy and security issues pose challenges. Key players include AbbVie Inc., Amgen Inc., AstraZeneca Plc, and others.

Pharmaceutical and biotech companies often change names to reflect mission and focus. Notable changes include J&J renaming Janssen to Johnson & Johnson Innovative Medicine, BeiGene becoming BeOne Medicines, Vaccitech rebranding as Barinthus Biotherapeutics, Cullinan Oncology shifting to Cullinan Therapeutics, and Eliem Therapeutics renaming to Climb Bio.